SARS-CoV Peptide Antigen negative control
AYRPPNAPIL-acid
Description
Application Data
Description
-
SARS-CoV spike protein sequence negative control for HLA binding assays.
Application Data
-
Data Sheet Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1001709 Molecular Weight 1110.6 Sequence (one letter code) AYRPPNAPIL-acid
Sequence (three letter code) H-Ala-Tyr-Arg-Pro-Pro-Asn-Ala-Pro-Ile-Leu-OH
Purity >95% References Lv et al., (2009). Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV. BMC Immunol 10: 61. doi: 10.1186/1471-2172-10-61.
Manufactured in: United Kingdom Epitope HLA binding for cytokine, CTL and ELISPOT assays require positive and negative controls if they are available. For SARS-CoV antigens, the HBcAg-derived H-2b-restricted peptide HBcAg (131-140) AYRPPNAPIL from the spike protein sequence is a suitable negative control.